Further analysis revealed that ENHO’s upregulation in advanced stages of PAAD correlates with better overall survival (HR: 0.597, 95% CI: 0.419–0.852, p < 0.01), as well as improved PFS, DFI, and DSS. The gene discussed is ENHO; the disease is pancreatic adenocarcinoma.